Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real-life worldwide population

Prinzi, Federica Lo;Salani, Francesca;Camera, Silvia;Rizzato, Mario Domenico;Saborowski, Anna;Antonuzzo, Lorenzo;Rossari, Federico;Satake, Tomoyuki;Peeters, Frederik;Pressiani, Tiziana;Lucchetti, Jessica;Kim, Jin Won;Abidoye, Oluseyi;Rapposelli, Ilario Giovanni;Gallio, Chiara;Tamberi, Stefano;Finkelmeier, Fabian;Giordano, Guido;Chiara, Pircher;Chon, Hong Jae;Braconi, Chiara;Qaisar, Aitzaz;Pastorino, Alessandro;Castet, Florian;Tamburini, Emiliano;Yoo, Changhoon;Parisi, Alessandro;Diana, Anna;Scartozzi, Mario;Prager, Gerald W;Avallone, Antonio;Schirripa, Marta;Kim, Il Hwan;Perkhofer, Lukas;Oneda, Ester;Verrico, Monica;Couto, Nuno;Adeva, Jorge;Chan, Stephen L;Spinelli, Gian Paolo;Personeni, Nicola;Garajova, Ingrid;Rodriquenz, Maria Grazia;Leo, Silvana;Alvim, Cecilia Melo;Roque, Ricardo;Polito, Mariam Grazia;Di Giacomo, Emanuela;Farinea, Giovanni;Bartalini, Linda;Grelli, Giada;De Rosa, Antonio;Lavacchi, Daniele;Ikeda, Masafumi;Dekervel, Jeroen;Niger, Monica;Balsano, Rita;Tonini, Giuseppe;Kang, Minsu;Tesini, Giulia;Boccaccino, Alessandra;Himmelsbach, Vera;Landriscina, Matteo;Djaballah, Selma Ahcene;Bekaii-Saab, Tanios;Fornaro, Lorenzo;Masi, Gianluca;Vogel, Arndt;Lonardi, Sara;Rimini, Margherita;Rimassa, Lorenza;Casadei-Gardini, Andrea

2025-01-01

---

Abstract

In recent years, there has been increasing interest in the possible prognostic impact of concomitant medications in patients with cancer treated with immunotherapy combinations. This real-world analysis aims to evaluate the impact of concomitant medications on survival outcomes in patients with advanced biliary tract cancer (BTCs) treated with cisplatin, gemcitabine and durvalumab (CGD) therapy. The study cohort included patients with a diagnosis of advanced BTCs who were taking concomitant medications for their comorbidities before the start of CGD. The primary objectives were overall survival (OS) and progression-free survival (PFS). The initial population consisted of 666 patients, who were retrospectively collected from 41 sites in 12 countries. Data on concomitant medications were available for 493 patients. After a median follow-up of 8.8 months (95% CI: 7.8–9.8), patients who did not take steroids (prednisone >10 mg/day or equivalent) or nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids, before the start of CGD, had longer OS and PFS in univariate analysis. The multivariate analysis confirmed longer OS for patients who did not take steroids. Patients who did not take steroids had an OS of 14.8 months (95% CI: 13.1–29.1) versus 5.0 months (95% CI: 2.14–11.32) of patients who took prednisone >10 mg/day or equivalent. No differences were reported in terms of overall response rate (ORR), disease control rate (DCR) (p = 1.0 and p =.16, respectively), and safety profile between the two groups. Our analysis suggests that patients who did not receive steroids before the start of GCD had longer survival and highlighted the relevance of balancing concomitant medications and chemoimmunotherapy.